


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (I)



(I)

wherein:

Y represents C1 to 4 alkyl, C1 to 4 alkoxy, halogen, CN, C≡CH, NO₂, CH₂OH, CHO, COCH₃, NH₂, NHCHO, NHCOCH₃ or NHSO₂CH₃; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

T, U and W independently represent CX, N, NR¹³, O or S(O)_m, except that at least one of T, U and W must represent a heteroatom and except that not more than one of T, U and W may represent

NR^{13} , O or $S(O)_m$; m represents an integer 0, 1 or 2; and each X group independently represents H, C1 to 4 alkyl, C1 to 4 alkoxy, halogen, OH, SH, CN, $C\equiv CH$, $N(R^{14})_2$, NO_2 , CH_2OH , CHO , $COCH_3$ or $NHCHO$; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

V represents NR^7 , O, CH_2 , $S(O)_n$, OCH_2 , CH_2O , NR^7CH_2 , CH_2NR^7 , $CH_2S(O)_n$, $S(O)_nCH_2$, CH_2CH_2 or $CH=CH$;

n represents an integer 0, 1 or 2;

M represents C, and when M is bonded to a CH_2 moiety in V, then M may also represent N;

R^1 and R^8 independently represent H or Me[[.[]]];

R^2 represents C1 to 4 alkyl, C2 to 4 alkenyl, C2 to 4 alkynyl, C3 to 6 cycloalkyl or a 4 to 8 membered saturated heterocyclic ring incorporating one heteroatom selected from O, S and N; any of said groups being optionally further substituted by C1 to 4 alkyl, C1 to 4 alkoxy, C1 to 4 alkylthio, C3 to 6 cycloalkyl, halogen or phenyl; said phenyl group being optionally further substituted by one or more substituents selected independently from halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF_3 , OCF_3 , CN or NO_2 ;

or R^2 represents phenyl or a five or six membered aromatic heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally substituted by one or more substituents selected independently from halogen, C1 to

4 alkyl, C1 to 4 alkoxy, OH, CN, NO₂ or NR⁹R¹⁰; said alkyl or alkoxy group being optionally further substituted by one or more fluorine atoms;

R³ represents H, C1 to 4 alkyl or C3 to 6 cycloalkyl; said alkyl group being optionally substituted by C1 to 4 alkoxy, halogen, hydroxy, NR¹¹R¹², phenyl or a five or six membered aromatic or saturated heterocyclic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said phenyl or aromatic heterocyclic ring being optionally further substituted by halogen, C1 to 4 alkyl, C1 to 4 alkoxy, CF₃, OCF₃, CN or NO₂;

R⁷ and R¹⁴ independently represent H or C1 to 2 alkyl;

R⁴, R⁵, R⁶, R⁹, R¹⁰, R¹¹ and R¹² independently represent H or C1 to 4 alkyl;

R¹³ represents H, C1 to 4 alkyl, CHO, COCH₃, SO₂CH₃ or CF₃;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound of formula (I), according to Claim 1, wherein V represents S(O)_n and n represents 0.

3. (Currently amended) A compound according to Claim 1-~~or 2~~ wherein Y represents CN.

4. (Original) A compound of formula (I), according to Claim 1, which is:

3-[(1R,3S)-3-amino-4-hydroxy-1-phenylbutyl]thio]-2-thiophenecarbonitrile;

3-[(1R,3S)-3-amino-4-hydroxy-1-phenylbutyl]thio]-5-methyl-2-thiophenecarbonitrile;

or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

5. (Cancelled)

6. (Currently amended) A pharmaceutical composition comprising a compound of formula (I) according to ~~any one of Claims 1 to 4~~ Claim 1, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

7-12. (Cancelled)

13. (Currently amended) A method, the method comprising treating or preventing pain by administering ~~The use of~~ a compound of formula (I) as defined in ~~any one of Claims 1 to 4~~ Claim 1, or a pharmaceutically acceptable salt thereof, ~~in the manufacture of a medicament, for the treatment or prophylaxis of pain.~~

14. (Currently amended) A method, the method comprising treating or preventing an inflammatory disease comprising administering ~~The use of~~ a compound of formula (I) as defined in ~~any one of Claims 1 to 4~~ Claim 1, or a pharmaceutically acceptable salt thereof, in combination with a COX-2 inhibitor, ~~in the manufacture of a medicament, for the treatment or prophylaxis of inflammatory diseases.~~


15. (Currently amended) A method of treating, or reducing the risk of, human diseases or conditions in which inhibition of nitric oxide synthase activity is beneficial which comprises administering a therapeutically effective amount of a compound of formula (I), as defined in ~~any one of Claims 1 to 4~~ Claim 1, or a pharmaceutically acceptable salt thereof, to a person suffering from, or at increased risk of, such diseases or conditions.

16. (Currently amended) A method of treating, or reducing the risk of, inflammatory disease in a person suffering from, or at risk of, said disease, wherein the method comprises administering to the


person a therapeutically effective amount of a compound of formula (I), as defined in ~~any one of~~ Claims 1 to 4 Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof.

17. (Currently amended) A process for the preparation of a compound of formula (I), as defined in ~~any one of~~ Claims 1 to 4 Claim 1, or a pharmaceutically acceptable salt, enantiomer or racemate thereof, wherein the process comprises:

(a) reaction of a compound of formula (II)




wherein T, U, W, Y and M are as defined in Claim 1 and L¹ represents a leaving group, with a compound of formula (III)




wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁸ and V are as defined in Claim 1; or

(b) reaction of a compound of formula (IV)



wherein T, U, W, M, Y and V are as defined in Claim 1,
with a compound of formula (V)



wherein R¹, R², R³, R⁴, R⁵, R⁶ and R⁸ are as defined in Claim 1 and L² is a leaving group;

and where desired or necessary converting the resultant compound of formula (I), or another salt thereof, into a pharmaceutically acceptable salt thereof; or converting one compound of formula (I) into another compound of formula (I); and where desired converting the resultant compound of formula (I) into an optical isomer thereof.

18. (New) The method of claim 15, wherein it is predominantly inducible nitric oxide synthase that is inhibited.

19. (New) The method of claim 16, wherein the disease is inflammatory bowel disease.

20. (New) The method of claim 16, wherein the disease is rheumatoid arthritis.

Applicant : Mete et al.
Serial No. : To Be Assigned
Filed : Herewith
Page : 9 of 10

Attorney's Docket No.: 06275-430US1 / 100772-1P US

21. (New) The method of claim 16, wherein the disease is osteoarthritis.